外陰がんの世界市場レポート 2025年

外陰がん市場規模は、今後数年間で力強い成長が見込まれます。2029年の年間平均成長率（CAGR）は9.3％で、8億9,000万米ドルに成長します。予測期間の成長は、治療オプションに対する需要の増加、標的療法の採用増加、がんの早期診断への注目の高まり、個別化医療の重視、スクリーニングプログラムの拡大などに起因すると考えられます。この期間の主な動向としては、標的療法や併用療法の進歩、個別化医療の役割の増大、戦略的協働、ロボット支援手術の採用などが挙げられます。

腫瘍学研究および医療への投資の増加は、今後数年間の同市場の成長を牽引すると予想されます。これらの投資は、政府、製薬会社、研究機関、非公開投資家によって行われ、がんの理解、予防、診断、治療の向上を目指しています。世界のがん罹患率の上昇、精密医療の進歩、革新的な治療法に対する需要、臨床試験の拡大、政府および民間の資金提供イニシアティブ、標的療法や免疫療法の開発などが、こうした投資の急増に寄与しています。これらの資金提供は、早期診断の改善、標的療法や免疫療法などの治療選択肢の強化、より効果的な薬剤の臨床試験への資金提供、小児がん治療のインフラ強化、疾患の生物学的性質と進行の理解のための革新的研究の育成など、調査研究を支援しています。例えば、2024年5月、高度な分析を専門とするインドの情報技術企業IQVIAは、2023年の世界のがん医療への支出が2022年から250億米ドル増加して2,230億米ドルに達し、2028年には4,090億米ドルに達すると予測していると報告しました。その結果、がん研究・医療への投資が増加し、引き続き外陰がん市場を牽引しています。

また、個別化医療が重視されるようになっていることも、外陰がん市場の拡大に寄与すると予想されます。個別化医療とは、遺伝的、環境的、ライフスタイル的要因に基づいて、個々の患者に合わせた治療を行うことです。このアプローチは、患者固有の違いに対処することで治療効果を高め、副作用を最小限に抑えることができるため、支持を集めています。外陰がんの場合、個別化医療は患者の遺伝子プロファイルに基づいて治療を最適化し、治療成績の向上と副作用の軽減につながります。例えば、2024年2月、米国の非営利団体である個別化医療連合（Personalized Medicine Coalition）は、2023年にFDAが希少疾患患者向けに新規の個別化治療を16件承認し、2022年の6件から増加したと報告しました。したがって、個別化医療への注目の高まりが外陰がん市場の成長に寄与しています。

目次

第1章 エグゼクティブサマリー

第2章 市場の特徴

第3章 市場動向と戦略

第4章 市場- マクロ経済シナリオ金利、インフレ、地政学、新型コロナウイルス感染症の影響と回復が市場に与える影響を含むマクロ経済シナリオ

第5章 世界の成長分析と戦略分析フレームワーク

• 世界外陰がんPESTEL分析（政治、社会、技術、環境、法的要因、促進要因と抑制要因）
• 最終用途産業の分析
• 世界の外陰がん市場：成長率分析
• 世界の外陰がん市場の実績：規模と成長, 2019-2024
• 世界の外陰がん市場の予測：規模と成長, 2024-2029, 2034F
• 世界外陰がん総アドレス可能市場（TAM）

第6章 市場セグメンテーション

• 世界の外陰がん市場がんの種類別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 外陰部扁平上皮がん
• 外陰部黒色腫
• 腺がん
• 基底細胞がん
• 世界の外陰がん市場治療の種類別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 化学療法
• 手術
• レーザー手術
• 切除
• 外陰部皮剥切除術
• 根治的外陰切除術
• 放射線治療
• 生物学的療法
• 世界の外陰がん市場：流通チャネル別、実績と予測, 2019-2024, 2024-2029F, 2034F
• オンラインチャンネル
• オフラインチャンネル
• 世界の外陰がん市場：エンドユーザー別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 病院と診療所
• 調査・学術機関
• その他のエンドユーザー
• 世界の外陰がん市場外陰部扁平上皮がんの種類別サブセグメンテーション、実績と予測, 2019-2024, 2024-2029F, 2034F
• 角化扁平上皮がん
• 非角化扁平上皮がん
• 疣贅性がん
• 世界の外陰がん市場外陰部黒色腫の種類別サブセグメンテーション、実績と予測, 2019-2024, 2024-2029F, 2034F
• 粘膜黒色腫
• 末端黒子型黒色腫
• 結節性黒色腫
• 世界の外陰がん市場腺がんの種類別サブセグメンテーション、実績と予測, 2019-2024, 2024-2029F, 2034F
• バルトリン腺がん
• 乳腺外パジェット病関連腺がん
• 汗腺腺がん
• 世界の外陰がん市場基底細胞がんの種類別サブセグメンテーション、実績と予測, 2019-2024, 2024-2029F, 2034F
• 表在性基底細胞がん
• 結節性基底細胞がん
• 硬化性基底細胞がん

第7章 地域別・国別分析

• 世界の外陰がん市場：地域別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 世界の外陰がん市場：国別、実績と予測, 2019-2024, 2024-2029F, 2034F

第8章 アジア太平洋市場

第9章 中国市場

第10章 インド市場

第11章 日本市場

第12章 オーストラリア市場

第13章 インドネシア市場

第14章 韓国市場

第15章 西欧市場

第16章 英国市場

第17章 ドイツ市場

第18章 フランス市場

第19章 イタリア市場

第20章 スペイン市場

第21章 東欧市場

第22章 ロシア市場

第23章 北米市場

第24章 米国市場

第25章 カナダ市場

第26章 南米市場

第27章 ブラジル市場

第28章 中東市場

第29章 アフリカ市場

第30章 競合情勢と企業プロファイル

• 外陰がん市場：競合情勢
• 外陰がん市場：企業プロファイル
  • F. Hoffmann-La Roche Ltd Overview, Products and Services, Strategy and Financial Analysis
  • Merck And Co. Overview, Products and Services, Strategy and Financial Analysis
  • Bristol-Myers Squibb Company Overview, Products and Services, Strategy and Financial Analysis
  • Novartis AG Overview, Products and Services, Strategy and Financial Analysis
  • GlaxoSmithKline plc Overview, Products and Services, Strategy and Financial Analysis

第31章 その他の大手企業と革新的企業

• Amgen Inc.
• Siemens Healthineers
• Teva Pharmaceutical
• Regeneron Pharmaceuticals, Inc.
• Intuitive Surgical Operations Inc.
• Sun Pharmaceuticals Ltd.
• Genentech Inc
• Varian Medical Systems Inc.
• Ono Pharmaceuticals Co. Ltd.
• Elekta AB
• Accuray Incorporated.
• Xencor
• Nordion Inc.
• ISA Pharmaceuticals BV
• Alpha Tau Medical Ltd.

第32章 世界の市場競合ベンチマーキングとダッシュボード

第33章 主要な合併と買収

第34章 最近の市場動向

第35章 市場の潜在力が高い国、セグメント、戦略

• 外陰がん市場2029：新たな機会を提供する国
• 外陰がん市場2029：新たな機会を提供するセグメント
• 外陰がん市場2029：成長戦略
  • 市場動向に基づく戦略
  • 競合の戦略

第36章 付録

Vulvar cancer is a type of cancer that develops in the vulva, the external part of the female genitalia. It usually originates in the skin or tissues of the vulva and may affect the labia, clitoris, or vaginal opening. The most common type is squamous cell carcinoma, which is often associated with human papillomavirus (HPV) infection. Symptoms can include itching, pain, and visible growths or sores on the vulva.

The main types of vulvar cancer include vulvar squamous cell carcinoma (SCC), vulvar melanoma, adenocarcinoma, and basal cell carcinoma. Vulvar SCC originates in the squamous cells of the vulva and is the most prevalent form. Treatment options include chemotherapy, surgery, laser surgery, excision, skinning vulvectomy, radical vulvectomy, radiation therapy, and biologic therapy. These treatments are distributed through online and offline channels and are utilized by various end users, including hospitals and clinics, research and academic institutes, and other healthcare facilities.

The vulvar cancer market research report is one of a series of new reports from The Business Research Company that provides vulvar cancer market statistics, including vulvar cancer industry global market size, regional shares, competitors with a vulvar cancer market share, detailed vulvar cancer market segments, market trends and opportunities, and any further data you may need to thrive in the vulvar cancer industry. This vulvar cancer market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The vulvar cancer market size has grown strongly in recent years. It will grow from $0.57 billion in 2024 to $0.62 billion in 2025 at a compound annual growth rate (CAGR) of 9.7%. The growth in the historic period can be attributed to the rising adoption of immunotherapy, an increasing incidence of vulvar cancer, greater investments in research and development, expanding government initiatives, and the growing use of HPV vaccines.

The vulvar cancer market size is expected to see strong growth in the next few years. It will grow to $0.89 billion in 2029 at a compound annual growth rate (CAGR) of 9.3%. The growth in the forecast period can be attributed to the increasing demand for therapeutic options, the rising adoption of targeted therapies, a greater focus on early cancer diagnosis, an emphasis on personalized medicine, and the expansion of screening programs. Key trends during this period include advancements in targeted and combination therapies, the growing role of personalized medicine, strategic collaborations, and the adoption of robotic-assisted surgery.

The increasing investments in oncology research and medicine are expected to drive the growth of the vulvar cancer market in the coming years. These investments, made by governments, pharmaceutical companies, research institutions, and private investors, aim to advance the understanding, prevention, diagnosis, and treatment of cancer. The rising global cancer burden, advancements in precision medicine, demand for innovative therapies, expanding clinical trials, government and private funding initiatives, and the development of targeted and immunotherapy treatments contribute to this surge in investments. These financial contributions support vulvar cancer research by improving early diagnosis, enhancing treatment options such as targeted therapies and immunotherapy, funding clinical trials for more effective drugs, strengthening pediatric cancer care infrastructure, and fostering innovative research to understand the disease's biology and progression. For example, in May 2024, IQVIA, an India-based information technology company specializing in advanced analytics, reported that global spending on cancer medicine increased to $223 billion in 2023, reflecting a $25 billion rise from 2022, and is projected to reach $409 billion by 2028. As a result, increasing investments in oncology research and medicine continue to drive the vulvar cancer market.

The growing emphasis on personalized medicine is also expected to contribute to the expansion of the vulvar cancer market. Personalized medicine involves tailoring medical treatments to individual patients based on genetic, environmental, and lifestyle factors. This approach is gaining traction as it enhances treatment effectiveness and minimizes adverse effects by addressing patient-specific differences. In the case of vulvar cancer, personalized medicine helps optimize treatments based on a patient's genetic profile, leading to improved outcomes and reduced side effects. For example, in February 2024, the Personalized Medicine Coalition, a US-based non-profit organization, reported that the FDA approved 16 novel personalized therapies for patients with rare diseases in 2023, up from six in 2022. The increasing focus on personalized medicine is, therefore, contributing to the growth of the vulvar cancer market.

Leading companies in the vulvar cancer market are prioritizing innovations in cancer therapy, including advancements in alpha-radiation cancer therapy, to improve treatment efficacy and patient outcomes. Alpha-radiation cancer therapy involves the targeted delivery of alpha particles to tumor cells, causing localized damage to cancerous tissue while minimizing harm to surrounding healthy cells. For instance, in May 2023, Alpha Tau Medical Ltd., an Israel-based company, announced the first use of its Alpha DaRT alpha-radiation cancer therapy to treat squamous cell carcinoma of the vulva. The study, conducted at Addenbrooke's Hospital within the Cambridge University Hospitals NHS Foundation Trust, aims to recruit 10 participants to evaluate the therapy's safety and effectiveness. Alpha DaRT offers a targeted, minimally invasive treatment approach, highlighting its potential as a non-surgical option for vulvar cancer.

Major players in the vulvar cancer market are F. Hoffmann-La Roche Ltd, Merck and Co., Bristol-Myers Squibb Company, Novartis AG, GlaxoSmithKline plc, Amgen Inc., Siemens Healthineers, Teva Pharmaceutical, Regeneron Pharmaceuticals, Inc., Intuitive Surgical Operations Inc., Sun Pharmaceuticals Ltd., Genentech Inc, Varian Medical Systems Inc., Ono Pharmaceuticals Co. Ltd., Elekta AB, Accuray Incorporated., Xencor, Nordion Inc., ISA Pharmaceuticals BV, Alpha Tau Medical Ltd.

North America was the largest region in the vulvar cancer market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in vulvar cancer report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

The countries covered in the vulvar cancer market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The vulvar cancer market consists of revenues earned by entities by providing services such as diagnostic testing, clinical consultations, immunotherapy, targeted therapy, and post-treatment care and monitoring. The market value includes the value of related goods sold by the service provider or included within the service offering. The vulvar cancer market also includes sales of pharmaceuticals, immunotherapy drugs, targeted therapy medications, diagnostic kits, and medical devices for tumor detection and monitoring. Values in this market are 'factory gate' values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values and are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Vulvar Cancer Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on vulvar cancer market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

• Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
• Assess the impact of key macro factors such as conflict, pandemic and recovery, inflation and interest rate environment and the 2nd Trump presidency.
• Create regional and country strategies on the basis of local data and analysis.
• Identify growth segments for investment.
• Outperform competitors using forecast data and the drivers and trends shaping the market.
• Understand customers based on the latest market shares.
• Benchmark performance against key competitors.
• Suitable for supporting your internal and external presentations with reliable high quality data and analysis
• Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
• All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for vulvar cancer ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The vulvar cancer market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

• The market characteristics section of the report defines and explains the market.
• The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
• The forecasts are made after considering the major factors currently impacting the market. These include:

The forecasts are made after considering the major factors currently impacting the market. These include the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.

• Market segmentations break down the market into sub markets.
• The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
• The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
• The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.

Scope

• Markets Covered:1) By Cancer Type: Vulvar Squamous Cell Carcinoma; Vulvar Melanoma; Adenocarcinoma; Basal Cell Carcinoma
• 2) By Treatment Type: Chemotherapy; Surgery; Laser Surgery; Excision; Skinning Vulvectomy; Radical Vulvectomy; Radiation Therapy; Biologic Therapy
• 3) By Distribution Channel: Online Channel; Offline Channel
• 4) By End Users: Hospitals And Clinics; Research And Academic Institutes; Other End Users
• Subsegments:
• 1) By Vulvar Squamous Cell Carcinoma: Keratinizing Squamous Cell Carcinoma; Non-Keratinizing Squamous Cell Carcinoma; Verrucous Carcinoma
• 2) By Vulvar Melanoma: Mucosal Melanoma; Acral Lentiginous Melanoma; Nodular Melanoma
• 3) By Adenocarcinoma: Bartholin Gland Adenocarcinoma; Extramammary Paget's Disease-Associated Adenocarcinoma; Sweat Gland Adenocarcinoma
• 4) By Basal Cell Carcinoma: Superficial Basal Cell Carcinoma; Nodular Basal Cell Carcinoma; Morpheaform (Sclerosing) Basal Cell Carcinoma
• Companies Mentioned: F. Hoffmann-La Roche Ltd; Merck And Co.; Bristol-Myers Squibb Company; Novartis AG; GlaxoSmithKline plc
• Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
• Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
• Time series: Five years historic and ten years forecast.
• Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
• Data segmentations: country and regional historic and forecast data, market share of competitors, market segments.
• Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
• Delivery format: PDF, Word and Excel Data Dashboard.

Table of Contents

1. Executive Summary

2. Vulvar Cancer Market Characteristics

3. Vulvar Cancer Market Trends And Strategies

4. Vulvar Cancer Market - Macro Economic Scenario Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics And Covid And Recovery On The Market

5. Global Vulvar Cancer Growth Analysis And Strategic Analysis Framework

• 5.1. Global Vulvar Cancer PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
• 5.2. Analysis Of End Use Industries
• 5.3. Global Vulvar Cancer Market Growth Rate Analysis
• 5.4. Global Vulvar Cancer Historic Market Size and Growth, 2019 - 2024, Value ($ Billion)
• 5.5. Global Vulvar Cancer Forecast Market Size and Growth, 2024 - 2029, 2034F, Value ($ Billion)
• 5.6. Global Vulvar Cancer Total Addressable Market (TAM)

6. Vulvar Cancer Market Segmentation

• 6.1. Global Vulvar Cancer Market, Segmentation By Cancer Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Vulvar Squamous Cell Carcinoma
• Vulvar Melanoma
• Adenocarcinoma
• Basal Cell Carcinoma
• 6.2. Global Vulvar Cancer Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Chemotherapy
• Surgery
• Laser Surgery
• Excision
• Skinning Vulvectomy
• Radical Vulvectomy
• Radiation Therapy
• Biologic Therapy
• 6.3. Global Vulvar Cancer Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Online Channel
• Offline Channel
• 6.4. Global Vulvar Cancer Market, Segmentation By End Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Hospitals And Clinics
• Research And Academic Institutes
• Other End Users
• 6.5. Global Vulvar Cancer Market, Sub-Segmentation Of Vulvar Squamous Cell Carcinoma, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Keratinizing Squamous Cell Carcinoma
• Non-Keratinizing Squamous Cell Carcinoma
• Verrucous Carcinoma
• 6.6. Global Vulvar Cancer Market, Sub-Segmentation Of Vulvar Melanoma, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Mucosal Melanoma
• Acral Lentiginous Melanoma
• Nodular Melanoma
• 6.7. Global Vulvar Cancer Market, Sub-Segmentation Of Adenocarcinoma, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Bartholin Gland Adenocarcinoma
• Extramammary Paget's Disease-Associated Adenocarcinoma
• Sweat Gland Adenocarcinoma
• 6.8. Global Vulvar Cancer Market, Sub-Segmentation Of Basal Cell Carcinoma, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Superficial Basal Cell Carcinoma
• Nodular Basal Cell Carcinoma
• Morpheaform (Sclerosing) Basal Cell Carcinoma

7. Vulvar Cancer Market Regional And Country Analysis

• 7.1. Global Vulvar Cancer Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 7.2. Global Vulvar Cancer Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

8. Asia-Pacific Vulvar Cancer Market

• 8.1. Asia-Pacific Vulvar Cancer Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 8.2. Asia-Pacific Vulvar Cancer Market, Segmentation By Cancer Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 8.3. Asia-Pacific Vulvar Cancer Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 8.4. Asia-Pacific Vulvar Cancer Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

9. China Vulvar Cancer Market

• 9.1. China Vulvar Cancer Market Overview
• 9.2. China Vulvar Cancer Market, Segmentation By Cancer Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 9.3. China Vulvar Cancer Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 9.4. China Vulvar Cancer Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion

10. India Vulvar Cancer Market

• 10.1. India Vulvar Cancer Market, Segmentation By Cancer Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.2. India Vulvar Cancer Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.3. India Vulvar Cancer Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

11. Japan Vulvar Cancer Market

• 11.1. Japan Vulvar Cancer Market Overview
• 11.2. Japan Vulvar Cancer Market, Segmentation By Cancer Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.3. Japan Vulvar Cancer Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.4. Japan Vulvar Cancer Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

12. Australia Vulvar Cancer Market

• 12.1. Australia Vulvar Cancer Market, Segmentation By Cancer Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 12.2. Australia Vulvar Cancer Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 12.3. Australia Vulvar Cancer Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

13. Indonesia Vulvar Cancer Market

• 13.1. Indonesia Vulvar Cancer Market, Segmentation By Cancer Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.2. Indonesia Vulvar Cancer Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.3. Indonesia Vulvar Cancer Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

14. South Korea Vulvar Cancer Market

• 14.1. South Korea Vulvar Cancer Market Overview
• 14.2. South Korea Vulvar Cancer Market, Segmentation By Cancer Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.3. South Korea Vulvar Cancer Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.4. South Korea Vulvar Cancer Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

15. Western Europe Vulvar Cancer Market

• 15.1. Western Europe Vulvar Cancer Market Overview
• 15.2. Western Europe Vulvar Cancer Market, Segmentation By Cancer Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.3. Western Europe Vulvar Cancer Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.4. Western Europe Vulvar Cancer Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

16. UK Vulvar Cancer Market

• 16.1. UK Vulvar Cancer Market, Segmentation By Cancer Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.2. UK Vulvar Cancer Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.3. UK Vulvar Cancer Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

17. Germany Vulvar Cancer Market

• 17.1. Germany Vulvar Cancer Market, Segmentation By Cancer Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.2. Germany Vulvar Cancer Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.3. Germany Vulvar Cancer Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

18. France Vulvar Cancer Market

• 18.1. France Vulvar Cancer Market, Segmentation By Cancer Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.2. France Vulvar Cancer Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.3. France Vulvar Cancer Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

19. Italy Vulvar Cancer Market

• 19.1. Italy Vulvar Cancer Market, Segmentation By Cancer Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.2. Italy Vulvar Cancer Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.3. Italy Vulvar Cancer Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

20. Spain Vulvar Cancer Market

• 20.1. Spain Vulvar Cancer Market, Segmentation By Cancer Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.2. Spain Vulvar Cancer Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.3. Spain Vulvar Cancer Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

21. Eastern Europe Vulvar Cancer Market

• 21.1. Eastern Europe Vulvar Cancer Market Overview
• 21.2. Eastern Europe Vulvar Cancer Market, Segmentation By Cancer Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.3. Eastern Europe Vulvar Cancer Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.4. Eastern Europe Vulvar Cancer Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

22. Russia Vulvar Cancer Market

• 22.1. Russia Vulvar Cancer Market, Segmentation By Cancer Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.2. Russia Vulvar Cancer Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.3. Russia Vulvar Cancer Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

23. North America Vulvar Cancer Market

• 23.1. North America Vulvar Cancer Market Overview
• 23.2. North America Vulvar Cancer Market, Segmentation By Cancer Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.3. North America Vulvar Cancer Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.4. North America Vulvar Cancer Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

24. USA Vulvar Cancer Market

• 24.1. USA Vulvar Cancer Market Overview
• 24.2. USA Vulvar Cancer Market, Segmentation By Cancer Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.3. USA Vulvar Cancer Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.4. USA Vulvar Cancer Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

25. Canada Vulvar Cancer Market

• 25.1. Canada Vulvar Cancer Market Overview
• 25.2. Canada Vulvar Cancer Market, Segmentation By Cancer Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.3. Canada Vulvar Cancer Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.4. Canada Vulvar Cancer Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

26. South America Vulvar Cancer Market

• 26.1. South America Vulvar Cancer Market Overview
• 26.2. South America Vulvar Cancer Market, Segmentation By Cancer Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.3. South America Vulvar Cancer Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.4. South America Vulvar Cancer Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

27. Brazil Vulvar Cancer Market

• 27.1. Brazil Vulvar Cancer Market, Segmentation By Cancer Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.2. Brazil Vulvar Cancer Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.3. Brazil Vulvar Cancer Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

28. Middle East Vulvar Cancer Market

• 28.1. Middle East Vulvar Cancer Market Overview
• 28.2. Middle East Vulvar Cancer Market, Segmentation By Cancer Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 28.3. Middle East Vulvar Cancer Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 28.4. Middle East Vulvar Cancer Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

29. Africa Vulvar Cancer Market

• 29.1. Africa Vulvar Cancer Market Overview
• 29.2. Africa Vulvar Cancer Market, Segmentation By Cancer Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 29.3. Africa Vulvar Cancer Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 29.4. Africa Vulvar Cancer Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

30. Vulvar Cancer Market Competitive Landscape And Company Profiles

• 30.1. Vulvar Cancer Market Competitive Landscape
• 30.2. Vulvar Cancer Market Company Profiles
  • 30.2.1. F. Hoffmann-La Roche Ltd Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.2. Merck And Co. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.3. Bristol-Myers Squibb Company Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.4. Novartis AG Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.5. GlaxoSmithKline plc Overview, Products and Services, Strategy and Financial Analysis

31. Vulvar Cancer Market Other Major And Innovative Companies

• 31.1. Amgen Inc.
• 31.2. Siemens Healthineers
• 31.3. Teva Pharmaceutical
• 31.4. Regeneron Pharmaceuticals, Inc.
• 31.5. Intuitive Surgical Operations Inc.
• 31.6. Sun Pharmaceuticals Ltd.
• 31.7. Genentech Inc
• 31.8. Varian Medical Systems Inc.
• 31.9. Ono Pharmaceuticals Co. Ltd.
• 31.10. Elekta AB
• 31.11. Accuray Incorporated.
• 31.12. Xencor
• 31.13. Nordion Inc.
• 31.14. ISA Pharmaceuticals BV
• 31.15. Alpha Tau Medical Ltd.

32. Global Vulvar Cancer Market Competitive Benchmarking And Dashboard

33. Key Mergers And Acquisitions In The Vulvar Cancer Market

34. Recent Developments In The Vulvar Cancer Market

35. Vulvar Cancer Market High Potential Countries, Segments and Strategies

• 35.1 Vulvar Cancer Market In 2029 - Countries Offering Most New Opportunities
• 35.2 Vulvar Cancer Market In 2029 - Segments Offering Most New Opportunities
• 35.3 Vulvar Cancer Market In 2029 - Growth Strategies
  • 35.3.1 Market Trend Based Strategies
  • 35.3.2 Competitor Strategies

36. Appendix

• 36.1. Abbreviations
• 36.2. Currencies
• 36.3. Historic And Forecast Inflation Rates
• 36.4. Research Inquiries
• 36.5. The Business Research Company
• 36.6. Copyright And Disclaimer